Grufity logo
Grufity logo
INAB

INAB - IN8bio Inc Stock Price, Fair Value and News

$1.08+0.01 (+0.93%)
Market Closed as of 30 Jul 2026, 04:00 pm ET

Price Targets

INAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INAB Price Action

Last 7 days

-9.8%

Last 30 days

-18.9%

Last 90 days

-20%

Trailing 12 Months

-50.2%

INAB RSI Chart

INAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INAB Valuation

Market Cap

10.6M

Price/Earnings (Trailing)

-0.56

EV/EBITDA

0.48

Price/Free Cashflow

-0.73

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

INAB Fundamentals

INAB Earnings

Earnings (TTM)

-19.0M

Earnings Growth (Yr)

8.29%

Earnings Growth (Qtr)

-2.99%

INAB Profitability

Return on Equity

-83.32%

Return on Assets

-72.26%

Free Cashflow Yield

-136.69%

INAB Investor Care

Shares Dilution (1Y)

282.36%

Diluted EPS (TTM)

-2.57

Revenue & Growth

How IN8bio Inc generates revenue and covers its expenses, based on the latest reported earnings.

About IN8bio Inc

INAB
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
 CEO
 WEBSITEhttps://in8bio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES29

IN8bio Inc Frequently Asked Questions

INAB is the stock ticker symbol of IN8bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Jul 30 2026, market cap of IN8bio Inc is 10.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.